在瑞士过度负债和超重 - - 在一个研究不足的人群中,这是一个基本上未被探索的关联
1Epidemiology, Biostatistics and Prevention Institute (EBPI), University of Zurich, Zurich, Switzerland.
PloS one
|February 17, 2026
概括
在瑞士,负债累累的人患超重或肥胖的风险明显高. 这项研究强调了财务压力与不良健康结果之间的关键联系,特别是在弱势群体中.
科学领域:
- 公共卫生 公共卫生
- 社会学 社会学 社会学
- 卫生经济学 卫生经济学
背景情况:
- 过度负债和肥胖正在引起全球健康的担忧.
- 这两种情况都不成比例地影响了社会经济和教育水平较低的群体.
- 关于过度负债和肥胖的同时发生的研究有限,特别是在瑞士.
研究的目的:
- 调查瑞士过度负债和超重/肥胖之间的关系.
- 为了确定是否过度负债的个人表现出比普通人群更高的肥胖患病率.
主要方法:
- 采用了来自苏黎世州219名过度负债客户和1,997名普通人口受访者的调查数据.
- 使用后勤和波桑回归分析来计算赔率和风险比率.
- 对性别,年龄和教育水平等人口因素进行控制.
主要成果:
- 过度负债的个体显示,超重 (46%对38%) 和肥胖 (15%对9%) 的患病率显著更高.
- 过度负债导致体重过重的相对风险增加了20-36%,肥胖的相对风险增加了59-70%.
- 这些关联持续不论性别,年龄,教育程度,控制感,孤独感或抑郁症状.
结论:
- 在瑞士,超负债和肥胖之间存在统计学上显著的关联.
- 观察到的效应大小是显著的,但小于最初预期的.
- 调查结果强调,需要采取综合干预措施,解决金融和身体健康问题.
相关概念视频
Obesity
1.4K
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.4K
Drug Dosing: Obese Patients
279
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
279
Stress Prevention and Stress Management Techniques IV
279
Stress often leads to unhealthy habits like smoking, excessive drinking, and overeating, which offer short-term relief but ultimately increase long-term health risks. These behaviors create a cycle that temporarily lowers stress levels but can result in severe long-term health consequences. Breaking these habits is essential to reduce the risk of chronic diseases and improve overall well-being. Three primary changes that support better health include quitting smoking, reducing alcohol intake,...
279
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
302
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
302
Carbohydrate Metabolism
14.5K
Carbohydrates are polymers composed of molecules containing atoms of carbon, hydrogen and oxygen. One gram of carbohydrate can provide four kilo-calories of energy, which makes it the most efficient instant energy source.
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
14.5K
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
199
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
199


